ADAPTIMMUNE THERAPEUTICS PLC's ticker is ADAP and the CUSIP is 00653A107. A total of 49 filers reported holding ADAPTIMMUNE THERAPEUTICS PLC in Q4 2015. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2019 | $0 | -100.0% | 375 | 0.0% | 0.00% | – |
Q2 2019 | $1,000 | 0.0% | 375 | 0.0% | 0.00% | – |
Q1 2019 | $1,000 | -99.2% | 375 | -95.7% | 0.00% | – |
Q3 2018 | $119,000 | +13.3% | 8,823 | 0.0% | 0.00% | – |
Q2 2018 | $105,000 | +81.0% | 8,823 | 0.0% | 0.00% | – |
Q1 2018 | $58,000 | 0.0% | 8,823 | 0.0% | 0.00% | – |
Q4 2017 | $58,000 | -19.4% | 8,823 | 0.0% | 0.00% | – |
Q3 2017 | $72,000 | +50.0% | 8,823 | 0.0% | 0.00% | – |
Q2 2017 | $48,000 | 0.0% | 8,823 | 0.0% | 0.00% | – |
Q1 2017 | $48,000 | +37.1% | 8,823 | 0.0% | 0.00% | – |
Q4 2016 | $35,000 | -50.0% | 8,823 | -11.8% | 0.00% | – |
Q3 2016 | $70,000 | -58.8% | 9,998 | -52.2% | 0.00% | -100.0% |
Q2 2016 | $170,000 | +580.0% | 20,923 | +574.9% | 0.00% | – |
Q1 2016 | $25,000 | -32.4% | 3,100 | 0.0% | 0.00% | – |
Q4 2015 | $37,000 | +27.6% | 3,100 | +24.0% | 0.00% | – |
Q3 2015 | $29,000 | -12.1% | 2,500 | +37.0% | 0.00% | – |
Q2 2015 | $33,000 | – | 1,825 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Syncona Portfolio Ltd | 1,377,294 | $1,501,250 | 2.44% |
NEA Management Company, LLC | 17,079,779 | $18,616,958 | 1.29% |
Endurant Capital Management LP | 1,660,835 | $1,810,310 | 0.93% |
Matrix Capital Management Company, LP | 38,974,185 | $42,481,862 | 0.58% |
Long Focus Capital Management, LLC | 5,435,439 | $5,924,629 | 0.34% |
PFM Health Sciences, LP | 5,992,571 | $6,531,902 | 0.29% |
Key Client Fiduciary Advisors, LLC | 321,155 | $350,059 | 0.22% |
DAFNA Capital Management LLC | 351,064 | $382,660 | 0.12% |
Rock Springs Capital Management LP | 2,787,845 | $3,038,751 | 0.07% |
Baker Brothers Advisors | 9,830,877 | $10,715,656 | 0.06% |